Home » Stocks » TransMedics Group

TransMedics Group, Inc. (TMDX)

Stock Price: $17.42 USD 0.81 (4.88%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 472.28M
Revenue (ttm) 26.46M
Net Income (ttm) -35.50M
Shares Out 27.11M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $17.42
Previous Close $16.61
Change ($) 0.81
Change (%) 4.88%
Day's Open 16.91
Day's Range 16.70 - 17.72
Day's Volume 137,450
52-Week Range 10.10 - 28.90

More Stats

Market Cap 472.28M
Enterprise Value 433.50M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.11M
Float 15.06M
EPS (basic) -1.82
EPS (diluted) -1.85
FCF / Share -1.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.08M
Short Ratio 4.03
Short % of Float 8.40%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.85
PB Ratio 7.70
Revenue 26.46M
Operating Income -31.66M
Net Income -35.50M
Free Cash Flow -33.64M
Net Cash 38.79M
Net Cash / Share 1.43
Gross Margin 52.40%
Operating Margin -119.65%
Profit Margin -134.20%
FCF Margin -127.13%
ROA -29.17%
ROE -204.11%
ROIC -31.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.00*
(14.81% upside)
Low
15.0
Current: 17.42
High
25.0
Target: 20.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue23.6013.027.696.21
Revenue Growth81.33%69.38%23.77%-
Gross Profit13.865.732.140.77
Operating Income-29.60-20.24-20.43-22.99
Net Income-33.55-23.76-20.82-24.07
Shares Outstanding14.201.364.654.50
Earnings Per Share-2.36-17.48-4.48-5.35
Operating Cash Flow-32.29-25.98-23.10-24.11
Capital Expenditures-0.17-0.42-0.26-1.48
Free Cash Flow-32.45-26.40-23.36-25.59
Cash & Equivalents81.1920.7425.160.00
Total Debt34.1533.678.65-
Net Cash / Debt47.04-12.9316.510.00
Assets10542.1637.00-
Liabilities50.6547.8819.21-
Book Value54.65-192-169-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name TransMedics Group, Inc.
Country United States
Employees 109
CEO Waleed H. Hassanein

Stock Information

Ticker Symbol TMDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: TMDX

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.